Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Intravenous Doses of CM-101 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs CM 101 (Primary)
- Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis; Systemic scleroderma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Chemomab Therapeutics
- 18 Oct 2020 According to a ChemomAb media release, data from this trial will be presented as a late-breaking poster presentation at The Liver Meeting Digital Experience™ 2020 of the American Association for the Study of Liver Diseases (AASLD).
- 08 Dec 2017 New trial record